Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Prior authorization Horizant 600mg Medicare?
Horizant is a prodrug of gabapentin, meaning the body converts it into gabapentin after absorption. Unlike generic gabapentin, Horizant was specifically engineered for sustained, predictable absorption in the lower intestine.
How Medicare Part D Covers Horizant 600mg
Medicare Part D is the outpatient prescription drug benefit. Horizant falls under Part D, not Part B, because it is a self-administered oral medication. For payer-specific handling of these requests, see our Medicare prior authorization services.
Typical Part D formulary placement for Horizant:
| Item | Details |
|---|---|
| Tier: | Tier 4 (non-preferred brand) in most Part D plans |
| PA required: | Yes, in the majority of Part D plans |
| Step therapy: | Yes. Most plans require documented trial and failure of generic gabapentin and/or a dopamine agonist (pramipexole or ropinirole) before approving Horizant. When a trial is clinically inappropriate, a step therapy override can be requested |
| Quantity limit: | Typically 30 tablets per 30 days (600mg strength for RLS) or 60 tablets per 30 days (600mg strength for PHN) |
2026 Part D changes that affect Horizant:
- The Inflation Reduction Act caps Part D out-of-pocket costs at $2,000/year starting 2025, which may reduce financial pressure on Horizant patients
- CMS-0057-F requires Part D plans to support electronic PA APIs starting January 2026, which should accelerate Horizant PA decisions
Cost to patient with Part D coverage: Copays range from $47-$120/month depending on the plan and tier. Without PA approval, the patient pays full retail.
When Is Prior Authorization Required for Horizant?
PA is required in virtually all of these scenarios:
| Item | Details |
|---|---|
| New prescription: | First-time Horizant prescriptions almost always trigger PA under Part D |
| Plan change: | Patient switches Part D plans during Annual Enrollment. New plan requires a fresh PA even if the previous plan had approved it |
| PA renewal: | Most Horizant PAs expire after 12 months. The practice must resubmit before expiration to avoid treatment gaps |
| Dose change: | Switching from 600mg once daily (RLS) to 600mg twice daily (PHN) may trigger a new PA or modification request |
| Quantity limit exception: | If the prescriber requests more than the plan’s quantity limit, a separate exception request is needed |
When PA is NOT required: Rare. A small number of Part D plans place Horizant on Tier 3 (preferred brand) without PA, but these are exceptions. Always verify with the plan’s formulary before prescribing.
Medicare Part D Plans
- Patient has a confirmed diagnosis of moderate-to-severe RLS or PHN
- Patient has tried and failed (or has a documented contraindication to) generic gabapentin
- For RLS: patient has tried and failed (or has a documented contraindication to) at least one dopamine agonist (pramipexole or ropinirole)
- Prescriber is a physician, NP, or PA with appropriate scope of practice
- Prescription is for an FDA-approved indication and dose
Commercial Insurance (Cigna, Aetna, UnitedHealthcare, BCBS)
- Step therapy is standard. Cigna's published gabapentin step therapy policy requires trial and failure of generic gabapentin before Horizant
- Highmark's Pharmacy Policy Bulletin (J-0137) adds requirement for documented treatment duration of at least 30 days on the step therapy agent
- Most commercial payers approve for 12 months with annual renewal
Medicare Advantage (MA-PD Plans)
- Follow the same Part D formulary rules as standalone Part D plans
- MA plans may add additional utilization management. Some require peer-to-peer review before approval
- CMS OIG found that MA plans deny 3.2 million PA requests. Of those appealed, 81.7% are overturned. This means first-pass denials are often worth appealing
Medicaid (See state-specific section below) – State PDLs generally prefer generic gabapentin
Phase 1: Pre-Submission
Step 1: Verify formulary status Check the patient’s specific Part D plan formulary online (Medicare.gov Plan Finder or the plan’s website). Confirm Horizant’s tier, PA requirement, step therapy criteria, and quantity limits before writing the prescription.
Step 2: Gather clinical documentation Collect and organize: – Diagnosis (ICD-10: G25.81 for RLS, G53.0 or B02.29 for PHN) – Duration and severity of symptoms – Prior medication trials: dates started, doses used, duration of trial, reason for discontinuation (inefficacy, side effects, contraindication) – For RLS: polysomnography results if available, IRLS rating scale score – Prescriber’s letter of medical necessity explaining why Horizant is required over generic alternatives
Step 3: Complete the PA form Use the plan’s PA form (available on the plan’s provider portal) or submit through CoverMyMeds or Surescripts. Include all clinical documentation from Step 2.
Phase 2: Submission and Follow-Up
Step 4: Submit the PA request
- Electronic (preferred): Via the plan’s provider portal, CoverMyMeds, or the CMS-0057-F ePA API (available 2026)
- Fax: If electronic submission is not available. Include a cover sheet with plan member ID, prescriber NPI, drug name/strength/quantity, and diagnosis
Step 5: Track the request Standard decision timeline: 72 hours from complete submission. Expedited timeline (if health risk exists): 24 hours. Log the submission date, confirmation number, and expected decision date.
Step 6: Respond to payer requests Plans may request additional information (peer-to-peer review, additional chart notes). Respond within 24 hours to avoid automatic denial for “failure to respond.”
Step 7: Receive determination
- Approved: PA authorization number issued. Pharmacy can fill the prescription. Note the approval duration (usually 12 months) and set a renewal reminder for 30 days before expiration
- Denied: Proceed to appeal (see next section)
Top Denial Reasons for Horizant PA
| Reason | How to Fix |
|---|---|
| Step therapy not completed: | Payer says the patient has not tried generic gabapentin or a dopamine agonist. Fix: Submit pharmacy claims data or chart notes proving prior trials |
| Insufficient documentation: | Clinical records do not support the diagnosis or severity. Fix: Add IRLS scores, sleep study results, or specialist notes |
| Non-formulary or excluded drug: | Some plans exclude Horizant entirely. Fix: Request a formulary exception with clinical justification |
| Quantity exceeds limit: | Prescribed quantity exceeds plan’s limit. Fix: Submit a quantity limit exception with clinical rationale |
| Prescriber not authorized: | NP or PA prescribing in a state with restricted scope for controlled/specialty medications. Fix: Have the supervising physician co-sign or submit |
Appeal Process for Medicare Part D
Level 1: Redetermination — Request within 60 days of denial. The Part D plan must issue a decision within 7 days (standard) or 72 hours (expedited). Submit additional documentation not included in the original PA.
Level 2: Independent Review Entity (IRE) — If redetermination is denied, request IRE review within 60 days. An independent third party reviews the case. Decision within 7 days (standard) or 72 hours (expedited).
Level 3: Administrative Law Judge (ALJ) — Available if the amount in controversy meets the threshold ($185 in 2025). Hearing within 90 days of request.
Level 4: Medicare Appeals Council — Final administrative appeal level.
Level 5: Federal District Court — Judicial review. Rarely needed for drug PA appeals.
Pro tip: 81.7% of appealed Medicare PA denials are overturned (CMS OIG). If the clinical documentation supports the prescription, appealing is almost always worth the effort.
New York Medicaid
| Item | Details |
|---|---|
| Program: | NYRx Preferred Drug Program |
| Gabapentin IR status: | Preferred (no PA required) |
| Horizant status: | Non-preferred. PA required |
| PA criteria: | Documented trial and failure of generic gabapentin plus at least one dopamine agonist for RLS indication. For PHN, trial and failure of generic gabapentin alone may suffice |
| Submission: | Electronic PA via CoverMyMeds accepted |
| Managed care plans: | Healthfirst, Fidelis Care, Molina, UnitedHealthcare Community Plan maintain separate formularies. Horizant is generally non-preferred or excluded across all NY Medicaid managed care plans |
| Note: | Manufacturer copay cards are NOT valid for Medicaid patients |
New Jersey Medicaid (NJ FamilyCare)
| Item | Details |
|---|---|
| PDL status (April 2026): | Gabapentin IR is preferred. Horizant requires PA |
| MCOs: | UnitedHealthcare Community Plan, Aetna Better Health, Horizon NJ Health, WellPoint NJ, Amerigroup NJ |
| PA criteria: | Each MCO may apply criteria beyond the state PDL. Amerigroup’s published policy requires a diagnosis of RLS or PHN plus documented trial and failure of generic gabapentin |
| Submission: | Through the MCO’s pharmacy PA portal or CoverMyMeds |
| Approval duration: | Typically 12 months |
California Medi-Cal
| Item | Details |
|---|---|
| Program: | Medi-Cal Rx (fee-for-service pharmacy benefit) |
| Gabapentin IR status: | Covered without restriction via the Contract Drug List (CDL) |
| Horizant status: | Not on the CDL. Requires a Treatment Authorization Request (TAR) |
| TAR criteria: | Clinical justification including documented failure of generic gabapentin and, for RLS, failure of at least one dopamine agonist |
| Managed care: | LA Care, Health Net, Molina, and other Medi-Cal managed care plans maintain separate formularies. All require PA for Horizant |
| Processing time: | TARs are processed within 24 hours for urgent requests, 5 business days for standard requests |
Why Practices Outsource Specialty Drug PA (and When It Makes Sense)
Specialty drug PAs like Horizant consume disproportionate staff time compared to standard drug PAs. The documentation requirements are heavier, the step therapy criteria are more complex, and the denial-and-appeal cycle is longer.
The math on in-house Horizant PA:
- Average time per Horizant PA submission: 35-50 minutes
- Average follow-up time (tracking, responding to requests, peer-to-peer calls): 20-30 minutes
- Average appeal time (if denied): 45-90 minutes per level of appeal
- Fully loaded cost of a U.S.-based PA coordinator: $22-$28/hour (MGMA 2025 staffing data)
- Cost per Horizant PA (submission through approval): $18-$45 in labor alone
When outsourcing makes financial sense:
- Practice submits 15+ specialty drug PAs per week
- PA denial rate exceeds 20% (indicating documentation quality issues)
- Staff turnover in the PA role exceeds industry average (creating constant retraining costs)
- Practice operates in multiple states with varying Medicaid PA requirements
What a specialty PA outsourcing partner handles:
- Eligibility verification and formulary lookup before PA submission
- PA form completion with clinical documentation attachment
- Electronic and fax-based submission
- Denial management and appeal preparation
- PA renewal tracking and proactive resubmission
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
How Staffingly Handles Horizant and Specialty Drug PA
Staffingly provides dedicated prior authorization specialists trained on payer-specific criteria for neurology and specialty drugs including Horizant, gabapentin enacarbil, and other RLS/PHN medications.
What makes the approach different
| Reason | How to Fix |
|---|---|
| Payer-specific PA playbooks: | Each payer’s Horizant criteria (step therapy, quantity limits, documentation requirements) is mapped before the first submission. No guessing, no generic templates |
| Pre-submission scrubbing: | Every Horizant PA is reviewed for completeness before submission. Missing documentation is flagged and requested from the provider before the PA goes to the payer, reducing first-pass denial rates |
| Multi-state Medicaid coverage: | Specialists trained on NY, NJ, CA, and 47 other state Medicaid programs. Each state’s PDL and MCO requirements are tracked and updated as formularies change |
| Denial-to-appeal pipeline: | If a Horizant PA is denied, the appeal is initiated within 24 hours with supplemental documentation. 81.7% of appealed Medicare PA denials are overturned (CMS OIG) |
| EHR integration: | Staffingly works within 50+ EHR platforms to pull clinical documentation directly, reducing back-and-forth with the provider |
Staffingly locked stats:
- Clean claim rate: 99.2%
- Providers served: 800+
- Starting rate: $399/week (volume discounts to $299/week)
- Savings vs. in-house: 70%
- Go-live: 48-72 hours
- Certifications: SOC 2 Type II, HITRUST, ISO 27001, HIPAA Compliant
Q: Is Horizant the same as gabapentin?
A: No. Horizant (gabapentin enacarbil) is a prodrug of gabapentin with a different absorption mechanism. The body converts it into gabapentin after ingestion, but the extended-release profile provides more consistent blood levels. Horizant is FDA-approved for RLS. Generic gabapentin is not FDA-approved for RLS.
Q: Does Medicare Part D cover Horizant 600mg?
A: Most Part D plans include Horizant on their formulary, typically at Tier 4 (non-preferred brand). Coverage almost always requires prior authorization and step therapy (trying generic gabapentin and/or a dopamine agonist first).
Q: How long does the Horizant prior authorization take?
A: Standard Part D PA decisions are due within 72 hours of a complete submission. Expedited requests (when patient health is at risk) must be decided within 24 hours. In practice, electronic submissions through CoverMyMeds or ePA APIs often receive same-day or next-day decisions.
Q: What if my Horizant PA is denied?
A: File a redetermination (Level 1 appeal) within 60 days. Include any additional clinical documentation. CMS data shows 81.7% of appealed Medicare PA denials are overturned. If the redetermination is denied, escalate to the Independent Review Entity (Level 2).
Q: Is there a generic for Horizant?
A: As of 2026, there is no generic version of gabapentin enacarbil. This is one reason payers require PA, because no lower-cost bioequivalent alternative exists within the gabapentin enacarbil class.
Q: How much does Horizant cost with Medicare Part D?
A: With Part D coverage and an approved PA, typical copays range from $47-$120/month depending on the plan and cost-sharing tier. The 2025 Inflation Reduction Act cap of $2,000/year on Part D out-of-pocket costs may further reduce annual exposure. Without coverage, retail price is $503-$676/month (GoodRx, 2026).
Q: Can Medicaid patients use the Horizant copay savings card?
A: No. Federal rules prohibit manufacturer copay assistance for patients enrolled in Medicaid, Medicare, or other government-funded programs. Medicaid patients must rely on their state program's PA process and formulary coverage.
Q: Does Staffingly handle Horizant PA specifically?
A: Yes. Staffingly's prior authorization specialists are trained on Horizant-specific payer criteria, step therapy documentation, and denial appeal workflows. The team operates across 50+ EHR platforms and handles multi-state Medicaid PA requirements.
